189 related articles for article (PubMed ID: 22144483)
1. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
[TBL] [Abstract][Full Text] [Related]
2. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
[TBL] [Abstract][Full Text] [Related]
3. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
4. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
[TBL] [Abstract][Full Text] [Related]
5. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
6. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
7. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
Corthier G; Muller MC; Wilkins TD; Lyerly D; L'Haridon R
Infect Immun; 1991 Mar; 59(3):1192-5. PubMed ID: 1900059
[TBL] [Abstract][Full Text] [Related]
8. Equine hyperimmune serum protects mice against Clostridium difficile spore challenge.
Yan W; Shin KS; Wang SJ; Xiang H; Divers T; McDonough S; Bowman J; Rowlands A; Akey B; Mohamed H; Chang YF
J Vet Sci; 2014; 15(2):249-58. PubMed ID: 24136208
[TBL] [Abstract][Full Text] [Related]
9. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
10. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
11. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.
Kink JA; Williams JA
Infect Immun; 1998 May; 66(5):2018-25. PubMed ID: 9573084
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
15. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
[TBL] [Abstract][Full Text] [Related]
16. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
17. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
18. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Steele J; Mukherjee J; Parry N; Tzipori S
J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
[TBL] [Abstract][Full Text] [Related]
19. Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.
Hong HA; Hitri K; Hosseini S; Kotowicz N; Bryan D; Mawas F; Wilkinson AJ; van Broekhoven A; Kearsey J; Cutting SM
Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28167669
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
